The impact of pravastatin therapy on long-term outcome in patients with metabolic syndrome undergoing complete coronary revascularization

Circulation Journal

Volumn 73, Issue 11, 2009, Pages 2104-2109

  Kasai, Takatoshi ^a   Miyauchi, Katsumi ^a   Kajimoto, Kan ^a   Kubota, Naozumi ^a   Kurata, Takeshi ^a   Amano, Atsushi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Coronary artery bypass grafting; Mortality; Percutaneous coronary intervention; Statin

Indexed keywords

PRAVASTATIN;

ADULT; AGED; ARTICLE; BODY MASS; BYPASS SURGERY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; METABOLIC SYNDROME X; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REVASCULARIZATION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 73249148457     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0122     Document Type: Article

References (33)

1. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
2. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 385-390.
3. Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T, et al. Metabolic syndrome and cardiac disease in Japanese Men: Applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese Men - The Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203-208.
4. Eberly LE, Prineas R, Cohen JD, Vazquez G, Zhi X, Neaton JD, et al; Multiple Risk Factor Intervention Trial Research Group. Metabolic syndrome: Risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006; 29: 123-130.
5. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: Prospective, population based cohort study. BMJ 2006; 332: 878-882.
6. Kasai T, Miyauchi K, Kurata T, Ohta H, Okazaki S, Miyazaki T, et al. Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. Circ J 2006; 70: 1531-1537.
7. Kajimoto K, Kasai T, Miyauchi K, Hirose H, Yanagisawa N, Yamamoto T, et al. Metabolic syndrome predicts 10-year mortality in non-diabetic patients following coronary artery bypass surgery. Circ J 2008; 72: 1481-1486.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
11. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Event Trial Investigators. N Engl J Med 1996; 335: 1001-1009.
12. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
13. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
14. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718.
15. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149-1158.
16. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
17. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
18. Liao JK. Beyond lipid lowering: The role of statins in vascular protection. Int J Cardiol 2002; 86: 5-18.
19. Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, et al, Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heartdisease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004; 27: 1735-1740.
20. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 2005; 28: 2508-2513.
21. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al; for the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet 2006; 368: 919-928.
22. Jones EL, Weintraub WS. The importance of completeness of revascularization during long-term follow-up after coronary artery operations. J Thorac Cardiovasc Surg 1996; 112: 227-237.
23. McLellan CS, Ghali WA, Labinaz M, Davis RB, Galbraith PD, Southern DA, et al, Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators. Association between completeness of percutaneous coronary revascularization and postprocedure outcomes. Am Heart J 2005; 150: 800-806.
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752.
25. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity: New criteria for 'obesity disease' in Japan. Circ J 2002; 66: 987-992.
26. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
27. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with Multivessel coronary artery disease and high-risk features. Circulation 2004; 109: 2290-2295.
28. Kasai T, Miyauchi K, Kurata T, Satoh H, Ohta H, Tanimoto K, et al. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int J Cardiol 2007; 114: 210-217.
29. Ikeda E, Kasai T, Kajimoto K, Miyauchi K, Kubota N, Kurata T, et al. Dipyridamole therapy improves long-term survival after complete revascularization in patients with impaired cardiac function: A propensity analysis. Circ J 2008; 72: 1588-1593.
30. Sakamoto K, Sakamoto T, Ogawa H; Kumamoto Joint Research on Hypercholesterolemia Investigators. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: A pilot study. Clin Ther 2006; 28: 1012-1021.
31. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
32. Yee A, Majumdar SR, Simpson SH, McAlister FA, Tsuyuki RT, Johnson JA. Statin use in Type 2 diabetes mellitus is associated with a delay in starting insulin. Diabet Med 2004; 21: 962-967.
33. Radford MJ, Foody JM. How do observational studies expand the evidence base for therapy? JAMA 2001; 286: 1228-1230.